CANCER COMMUN 润色咨询

Cancer Communications

出版年份:2015 年文章数:220 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:8.2% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2024-01-23 crgbjhffbnhfxc 来自湖北省

    审稿好慢 小修都快两个月 有一样的吗

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2024-02-20 146dd4e0m79(暂无昵称) 来自江苏省

    各位前辈问一下,pending recommendation是什么意思,大概都持续多久?

    9

    展开9条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2024-03-01 12056da9m23(暂无昵称) 来自香港

    这个杂志一般几天编辑决定送审呢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2023-12-24 Jojo 来自北京

    请问Pending Editor Assignment多久呀

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2023-11-01 ms6000000767028824 来自广西

    审稿速度:12.0 | 投稿命中率:50.0
    经验分享:审稿2个月以上,返修2次,总时长超过6个月

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2022-03-03 life2020hard

    10天了还在,initial checking.......

    14

    展开14条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2023-06-29 侠胆医心 来自香港

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:转化医学;肿瘤转移;鼻咽癌
    经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。
    在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。
    Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2023-04-23 ms6000001944827421 来自上海

    垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2021-03-23 zyn930812

    最近有人投吗?一周多了,还在初审呢

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2183501, encodeId=498a21835014e, content=审稿好慢 小修都快两个月 有一样的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230618/9b2d932b46ee4a64beb72ae0d5e09357/4e66ffa5af414b5693f6683eb14c8bfb.jpg, createdBy=4c042515011, createdName=crgbjhffbnhfxc, createdTime=Tue Jan 23 20:47:54 CST 2024, time=2024-01-23, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2188267, encodeId=2566218826e84, content=各位前辈问一下,pending recommendation是什么意思,大概都持续多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5ab5172610, createdName=146dd4e0m79(暂无昵称), createdTime=Tue Feb 20 10:32:39 CST 2024, time=2024-02-20, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190368, encodeId=c05a2190368ff, content=这个杂志一般几天编辑决定送审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf9a2172855, createdName=12056da9m23(暂无昵称), createdTime=Fri Mar 01 11:45:24 CST 2024, time=2024-03-01, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2176940, encodeId=069721e69401e, content=请问Pending Editor Assignment多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Sun Dec 24 22:20:00 CST 2023, time=2023-12-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2166029, encodeId=b3fd216602941, content=审稿速度:12.0 | 投稿命中率:50.0<br>经验分享:审稿2个月以上,返修2次,总时长超过6个月, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29042719, createdName=ms6000000767028824, createdTime=Wed Nov 01 10:40:42 CST 2023, time=2023-11-01, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=1199064, encodeId=640a11990645f, content=10天了还在,initial checking......., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11345587352, createdName=life2020hard, createdTime=Thu Mar 03 15:17:03 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2145340, encodeId=c2d5214534000, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:转化医学;肿瘤转移;鼻咽癌<br>经验分享:2023年6月28日,科睿唯安(Clarivate Analytics)发布了2022年期刊引证报告(Journal Citation Reports,JCR)。由中山大学肿瘤防治中心主办的国产高水平肿瘤学国际期刊 Cancer Communications (CC) 2022年影响因子为 16.2,位列全球241本 Oncology 学科类期刊第15位(Q1区)。<br>在中国科学院文献情报中心发布的《2022年中国科学院文献情报中心期刊分区表》中,Cancer Communications 再次进入医学大类1区Top期刊行列,同时继续位列肿瘤学小类1区。<br>Cancer Communications 在主编徐瑞华教授带领下稳步发展,期刊学术影响力不断提升,逐步进入全球高水平肿瘤学期刊阵营。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Jun 29 05:47:19 CST 2023, time=2023-06-29, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2127832, encodeId=423f212e83298, content=垃圾杂志找的什么破审稿人,审稿意见粗看言辞犀利细看狗屁不通,导致编辑直接给拒了,最离谱的就是指着一个EdU实验图说我IF染色分子定位不对,而且敲减组的荧光并没有显著减少。EdU还有别称叫IF吗?我文章里连IF都没提到过,能不能不要找连实验都没做过的人来审稿?别耽误人了行不行,简直离谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18a58420111, createdName=ms6000001944827421, createdTime=Sun Apr 23 14:46:54 CST 2023, time=2023-04-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=950327, encodeId=4f1b95032e09, content=最近有人投吗?一周多了,还在初审呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80135179168, createdName=zyn930812, createdTime=Tue Mar 23 12:20:26 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904182, encodeId=f8dc90418201, content=投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83e72477273, createdName=152244e1c4m, createdTime=Wed Dec 02 10:27:00 CST 2020, time=2020-12-02, status=1, ipAttribution=)]
    2020-12-02 152244e1c4m

    投了一周,还在格式审查,编号1100+,难道现在投稿数这么多吗?

    4

    展开4条回复
共150条页码: 1/15页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分